Koomesh
Journal of Semnan University of Medical Sciences
Image Credit:koomesh
Outlines
Effectiveness of NeuroAge Capsules on Mini-Mental State examination and Activities of Daily Living in Patients with Alzheimer's Disease: A Randomized Clinical Trial
Abstract
Background: Alzheimer's is a progressive neurodegenerative disease that accounts for 60 - 80% of dementia cases. Since no definitive treatment has been found for Alzheimer's disease, the search for new treatments is still ongoing.
Objectives: In this study, the effectiveness of NeuroAge capsules on mini-mental state examination (MMSE) and activities of daily living (ADL) in these patients was measured.
Materials and Methods: This study was a double-blind clinical trial that was conducted in 1401. The studied sample included 86 Alzheimer's patients treated with donepezil who had visited the clinic of Al-Zahra Hospital and were included in the study by census. Patients were randomly divided into case and control groups. Neuroage capsules were added to the previous drug in the case group and placebo in the control group. All patients responded to MMSE and ADL before and after 12 weeks.
Results: The results showed that the effect of time on MMSE and ADL was significant (P < 0.05), but the effect of consumption of NeuroAge capsules on MMSE and ADL was not significant (P < 0.05). The average MMSE and ADL had significantly decreased over time, but this decrease did not show a significant difference in the two groups (P < 0.05).
Conclusion: Adding Neuroage capsules to the treatment regimen of Alzheimer's patients treated with donepezil does not affect MMSE and ADL.
Highlights
References
- 1.Tang Y, Lutz MW, Xing Y. A systems-based model of Alzheimer's disease. Alzheimers Dement. 2019;15(1):168-71. [PubMed ID:30102884]. https://doi.org/10.1016/j.jalz.2018.06.3058.
- 2.Nabizadeh A, Sheikhalishahi ZS, Asadinezhad H, Kazemi H. [The Effect of Microbiota on miRNA Alteration in Alzheimer's Disease: A Review Study]. Koomesh 2023;25(5):375-. Persian.
- 3.Kumar A, Sidhu J, Lui F, Tsao JW. Alzheimer Disease. Treasure Island (FL); 2025.
- 4.Karimi Firouzjaei F, Mashayekh Pour MA, Shabani E, Jamshidi Burkhani MR. [The role of environmental risk factors in Alzheimer's disease]. Koomesh 2023;25(5):602-. Persian.
- 5.Zilberzwige-Tal S, Gazit E. Go with the Flow-Microfluidics Approaches for Amyloid Research. Chem Asian J. 2018;13(22):3437-47. [PubMed ID:30117682]. https://doi.org/10.1002/asia.201801007.
- 6.Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res. 2018;7. [PubMed ID:30135715]. [PubMed Central ID:PMC6073093]. https://doi.org/10.12688/f1000research.14506.1.
- 7.Gandolfi S, Marchini G, Caporossi A, Scuderi G, Tomasso L, Brunoro A. Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020;12(3). [PubMed ID:32197303]. [PubMed Central ID:PMC7146438]. https://doi.org/10.3390/nu12030793.
- 8.Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000;60(7):989-92. [PubMed ID:10974208]. https://doi.org/10.1016/s0006-2952(00)00436-6.
- 9.Bermejo PE, Dorado R, Zea-Sevilla MA. Role of Citicoline in Patients With Mild Cognitive Impairment. Neurosci Insights. 2023;18:26331055231152496. [PubMed ID:36818199]. [PubMed Central ID:PMC9936398]. https://doi.org/10.1177/26331055231152496.
- 10.Saiz-Vazquez O, Gracia-Garcia P, Ubillos-Landa S, Puente-Martinez A, Casado-Yusta S, Olaya B, et al. Depression as a Risk Factor for Alzheimer's Disease: A Systematic Review of Longitudinal Meta-Analyses. J Clin Med. 2021;10(9). [PubMed ID:33919227]. [PubMed Central ID:PMC8122638]. https://doi.org/10.3390/jcm10091809.
- 11.Kondo DG, Sung YH, Hellem TL, Delmastro KK, Jeong EK, Kim N, et al. Open-label uridine for treatment of depressed adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2011;21(2):171-5. [PubMed ID:21486171]. [PubMed Central ID:PMC3080753]. https://doi.org/10.1089/cap.2010.0054.
- 12.Mironova GD, Khrenov MO, Talanov EY, Glushkova OV, Parfenyuk SB, Novoselova TV, et al. The role of mitochondrial KATP channel in anti-inflammatory effects of uridine in endotoxemic mice. Arch Biochem Biophys. 2018;654:70-6. [PubMed ID:30009781]. https://doi.org/10.1016/j.abb.2018.07.006.
- 13.Goren B, Cakir A, Sevinc C, Serter Kocoglu S, Ocalan B, Oy C, et al. Uridine treatment protects against neonatal brain damage and long-term cognitive deficits caused by hyperoxia. Brain Res. 2017;1676:57-68. [PubMed ID:28919465]. https://doi.org/10.1016/j.brainres.2017.09.010.
- 14.Ismail N, Kureishy N, Church SJ, Scholefield M, Unwin RD, Xu J, et al. Vitamin B5 (d-pantothenic acid) localizes in myelinated structures of the rat brain: Potential role for cerebral vitamin B5 stores in local myelin homeostasis. Biochem Biophys Res Commun. 2020;522(1):220-5. [PubMed ID:31759626]. [PubMed Central ID:PMC6977085]. https://doi.org/10.1016/j.bbrc.2019.11.052.
- 15.Leonardi R, Jackowski S. Biosynthesis of Pantothenic Acid and Coenzyme A. EcoSal Plus. 2007;2(2). [PubMed ID:26443589]. [PubMed Central ID:PMC4950986]. https://doi.org/10.1128/ecosalplus.3.6.3.4.
- 16.Yang A, Du L, Gao W, Liu B, Chen Y, Wang Y, et al. Associations of cortical iron accumulation with cognition and cerebral atrophy in Alzheimer's disease. Quant Imaging Med Surg. 2022;12(9):4570-86. [PubMed ID:36060596]. [PubMed Central ID:PMC9403583]. https://doi.org/10.21037/qims-22-7.
- 17.Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA. Iron: a pathological mediator of Alzheimer disease? Dev Neurosci. 2002;24(2-3):184-7. [PubMed ID:12401957]. https://doi.org/10.1159/000065696.
- 18.Brosnan JT. Interorgan amino acid transport and its regulation. J Nutr. 2003;133(6 Suppl 1):2068S-72S. [PubMed ID:12771367]. https://doi.org/10.1093/jn/133.6.2068S.
- 19.Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr. 2000;130(4S Suppl):1016S-22S. [PubMed ID:10736373]. https://doi.org/10.1093/jn/130.4.1016S.
- 20.Alvarez XA, Sampedro C, Lozano R, Cacabelos R. Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Methods Find Exp Clin Pharmacol. 1999;21(8):535-40. [PubMed ID:10599052]. https://doi.org/10.1358/mf.1999.21.8.794835.
- 21.Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study. Clin Drug Investig. 2016;36(12):1059-65. [PubMed ID:27587069]. https://doi.org/10.1007/s40261-016-0454-3.
- 22.Rasmussen J. The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer's disease? Clin Interv Aging. 2019;14:1481-92. [PubMed ID:31616139]. [PubMed Central ID:PMC6699494]. https://doi.org/10.2147/CIA.S211739.
- 23.Xu J, Patassini S, Begley P, Church S, Waldvogel HJ, Faull RLM, et al. Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer's disease. Biochem Biophys Res Commun. 2020;527(3):676-81. [PubMed ID:32416962]. https://doi.org/10.1016/j.bbrc.2020.05.015.
- 24.Sang C, Philbert SA, Hartland D, Unwin RD, Dowsey AW, Xu J, et al. Coenzyme A-Dependent Tricarboxylic Acid Cycle Enzymes Are Decreased in Alzheimer's Disease Consistent With Cerebral Pantothenate Deficiency. Front Aging Neurosci. 2022;14:893159. [PubMed ID:35754968]. [PubMed Central ID:PMC9232186]. https://doi.org/10.3389/fnagi.2022.893159.
- 25.Nuzzo T, Mancini A, Miroballo M, Casamassa A, Di Maio A, Donati G, et al. High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease. Amino Acids. 2021;53(3):435-49. [PubMed ID:33616735]. https://doi.org/10.1007/s00726-021-02943-7.
- 26.Madeira C, Vargas-Lopes C, Brandao CO, Reis T, Laks J, Panizzutti R, et al. Elevated Glutamate and Glutamine Levels in the Cerebrospinal Fluid of Patients With Probable Alzheimer's Disease and Depression. Front Psychiatry. 2018;9:561. [PubMed ID:30459657]. [PubMed Central ID:PMC6232456]. https://doi.org/10.3389/fpsyt.2018.00561.
- 27.Hen J, Herrup K. Glutamine acts as a neuroprotectant against DNA damage, beta-amyloid and H2O2-induced stress. PLoS One. 2012;7(3):e33177. [PubMed ID:22413000]. [PubMed Central ID:PMC3297635]. https://doi.org/10.1371/journal.pone.0033177.
- 28.Wang Y, Wang Q, Li J, Lu G, Liu Z. Glutamine Improves Oxidative Stress through the Wnt3a/beta-Catenin Signaling Pathway in Alzheimer's Disease In Vitro and In Vivo. Biomed Res Int. 2019;2019:4690280. [PubMed ID:31119171]. [PubMed Central ID:PMC6500677]. https://doi.org/10.1155/2019/4690280.
- 29.Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry. 2000;57(1):47-53. [PubMed ID:10632232]. https://doi.org/10.1001/archpsyc.57.1.47.
- 30.Ayton S, Wang Y, Diouf I, Schneider JA, Brockman J, Morris MC, et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatry. 2020;25(11):2932-41. [PubMed ID:30778133]. [PubMed Central ID:PMC6698435]. https://doi.org/10.1038/s41380-019-0375-7.
- 31.Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J. 2002;43(1):28-32. [PubMed ID:11828555].
- 32.Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics. 2009;2:2. [PubMed ID:19133145]. [PubMed Central ID:PMC2672098]. https://doi.org/10.1186/1755-8794-2-2.
- 33.Liu JL, Fan YG, Yang ZS, Wang ZY, Guo C. Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic Implications. Front Neurosci. 2018;12:632. [PubMed ID:30250423]. [PubMed Central ID:PMC6139360]. https://doi.org/10.3389/fnins.2018.00632.
Copyright
© 2025, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Efficacy of Donepezil in Improving Cognitive Impairment Induced by Electroconvulsive Therapy in Patients with Mood Disorders: A Randomized, Double-blind, Placebo-Controlled Trial
Zarean E, Sedehi M, Heshmati Y. Efficacy of Donepezil in Improving Cognitive Impairment Induced by Electroconvulsive Therapy in Patients with Mood Disorders: A Randomized, Double-blind, Placebo-Controlled Trial. Iran J Psychiatry Behav Sci. 2021;15(3):e107598. doi: https://doi.org/10.5812/ijpbs.107598
Effect of Telenursing on Caregiver Burden of Care and Incidence of some Complications in Patients with Acute Stroke Discharged from Neurological Wards: A Randomized Control Trial
Hosseini A, Sharifi N, Dehghanrad F, Sharifipour E. Effect of Telenursing on Caregiver Burden of Care and Incidence of some Complications in Patients with Acute Stroke Discharged from Neurological Wards: A Randomized Control Trial. Shiraz E-Med J. 2022;23(8):e123479. doi: https://doi.org/10.5812/semj-123479
Study of the Neuroprotective Effects of Memantine in Patients with Mild to Moderate Ischemic Stroke
Kafi H, Salamzadeh J, Beladimoghadam N, Sistanizad M, Kouchek M. Study of the Neuroprotective Effects of Memantine in Patients with Mild to Moderate Ischemic Stroke. Iran J Pharm Res. 2014;13(2):e125541. doi: https://doi.org/10.22037/ijpr.2014.1511
Group-Based Exercise as a Therapeutic Strategy for the Improvement of Mental Outcomes in Mild to Moderate Alzheimer’s Patients in Low Resource Care Facilities
Shaw I, Cronje M, Shaw BS. Group-Based Exercise as a Therapeutic Strategy for the Improvement of Mental Outcomes in Mild to Moderate Alzheimer’s Patients in Low Resource Care Facilities. Asian J Sports Med. 2021;12(1):e106593. doi: https://doi.org/10.5812/asjsm.106593
The effectiveness of cognitive group therapy on reducing depression and anxiety in the Kermanshah older women
Azizi M, Momeni K. The effectiveness of cognitive group therapy on reducing depression and anxiety in the Kermanshah older women. J Clin Res Paramed Sci. 2014;3(3):e82119. doi:
Crossmark
Checking
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 0
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 4 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):